Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
20.39
+1.43 (7.54%)
Aug 15, 2025, 12:32 PM - Market open
Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older.
It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Scott Plesha |
Contact Details
Address: 4020 Stirrup Creek Drive, Suite 110 Durham, North Carolina 27703 United States | |
| Phone | 877 265 8266 |
| Website | pelthos.com |
Stock Details
| Ticker Symbol | PTHS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001919246 |
| ISIN Number | US1711261057 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Scott M. Plesha | Chief Executive Officer, President and Director |
| Sai Rangarao M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 10, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 8, 2025 | SCHEDULE 13G | Filing |
| Jul 3, 2025 | SCHEDULE 13D/A | Filing |
| Jul 3, 2025 | SCHEDULE 13D | Filing |
| Jul 2, 2025 | 8-K | Current Report |
| May 27, 2025 | DEFM14C | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |